| 24A720 |
Merck Sharp & Dohme Corporation v. Doris Albrecht, et al. |
Third Circuit |
2025-01-22 |
Presumed Complete |
|
drug-labeling failure-to-warn federal-regulations pharmaceutical-liability preemption product-liability |
Question not identified. |
| 24-5593 |
Otis Brandon v. Janssen Pharmaceuticals, et al. |
Fourth Circuit |
2024-09-20 |
Denied |
IFP |
drug-labeling fda-citations judicial-review medical-liability mental-capacity pharmaceutical-misconduct |
1) Did the lower courts fail to consider numerous ca.ses alleged
agianst the parmaceutical company Janssen and Johnson &
Johnson for misrepresentati… |
| 22-1180 |
Shire U.S., Inc., et al. v. Mark Blackburn |
Eleventh Circuit |
2023-06-07 |
Denied |
Amici (1) |
drug-labeling fda-preapproval FDA-regulations federal-preemption pliva-v-mensing preemption prescription-drugs state-law-claim state-law-claims unilateral-change unilateral-label-changes |
Whether a state-law claim is preempted if it places a duty on a drug manufacturer to unilaterally change FDA-approved language that appears in the Hig… |
| 21-1238 |
Ina Ann Rodman v. Otsuka America Pharmaceutical, Inc. |
Ninth Circuit |
2022-03-11 |
Denied |
Response Waived |
21-cfr-314-80 design-defect drug-labeling expert-testimony failure-to-warn misbranding pharmaceutical-liability post-marketing-surveillance summary-judgment wyeth-v-levine |
1. Whether Ms. Rodman presented admissible evidence in the form of Otsuka's failure to follow the admonition of 21 C.F.R. § 314.80 to conduct post-mar… |
| 20-1069 |
Janssen Pharmaceuticals, Inc., et al. v. A. Y., et al. |
Pennsylvania |
2021-02-05 |
Denied |
Amici (4) |
civil-liability drug-labeling fda-regulation federal-preemption impossibility-preemption off-label-use preemption state-tort-law |
Whether federal law preempts state-law claims that a manufacturer failed to provide adequate warnings relating to the off-label use of their products,… |
| 19-1444 |
GlaxoSmithKline LLC v. United Food and Commercial Workers Local 1776 and Participating Employers Health and Welfare Fund, et al. |
Third Circuit |
2020-07-01 |
Denied |
Amici (1)Response Waived |
avandia brand-name-drug brand-name-drugs conflict-preemption drug-labeling drug-manufacturer fda-preemption fda-regulations label-change material-information regulatory-compliance tort-claims |
Federal law preempts state -law tort claims where a brand- name drug's manufacturer provides the FDA with all material information in its possession a… |
| 18-803 |
Wendy B. Dolin v. GlaxoSmithKline, LLC, fka SmithKline Beecham Corporation |
Seventh Circuit |
2018-12-21 |
Denied |
Relisted (2) |
clinical-trials drug-labeling drug-manufacturer fda-regulations impossibility-preemption labeling-changes preemption truthful-risks unilateral-labeling-changes unilateral-warning wyeth-v-levine |
Does federal law prevent a drug manufacturer from enhancing its label to reflect truthful risks revealed in its clinical trials when the relevant FDA … |